Literature DB >> 19022942

Relationship between drug/metabolite exposure and impairment of excretory transport function.

Maciej J Zamek-Gliszczynski1, J Cory Kalvass, Gary M Pollack, Kim L R Brouwer.   

Abstract

The quantitative impact of excretory transport modulation on the systemic exposure to xenobiotics and derived metabolites is poorly understood. This article presents fundamental relationships between exposure and loss of a specific excretory process that contributes to overall clearance. The mathematical relationships presented herein were explored on the basis of hepatic excretory data for polar metabolites formed in the livers of various transporter-deficient rodents. Experimental data and theoretical relationships indicated that the fold change in exposure is governed by the relationship, 1/(1 - f(e)), where f(e) is the fraction excreted by a particular transport protein. Loss of function of a transport pathway associated with f(e) < 0.5 will have minor consequences (<2-fold) on exposure, but exposure will increase exponentially in response to loss of function of transport pathways with f(e) > 0.5. These mathematical relationships may be extended to other organs, such as the intestine and kidney, as well as to systemic drug exposure. Finally, the relationship between exposure and f(e) is not only applicable to complete loss of function of a transport pathway but also can be extended to partial inhibition scenarios by modifying the equation with the ratio of the inhibitor concentration and inhibition constant.

Mesh:

Substances:

Year:  2008        PMID: 19022942      PMCID: PMC2680528          DOI: 10.1124/dmd.108.023648

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  15 in total

1.  Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data.

Authors:  K Ueda; Y Kato; K Komatsu; Y Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2001-06       Impact factor: 4.030

2.  Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2).

Authors:  Makoto Sasaki; Hiroshi Suzuki; Kousei Ito; Takaaki Abe; Yuichi Sugiyama
Journal:  J Biol Chem       Date:  2001-12-17       Impact factor: 5.157

3.  Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats.

Authors:  Cuiping Chen; Dennis Scott; Elizabeth Hanson; Judy Franco; Edwin Berryman; Mario Volberg; Xingrong Liu
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

4.  Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment.

Authors:  Hao Xiong; Hiroshi Suzuki; Yuichi Sugiyama; Peter J Meier; Gary M Pollack; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2002-09       Impact factor: 3.922

5.  Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats.

Authors:  Kari T Kivistö; Olaf Grisk; Ute Hofmann; Konrad Meissner; Klaus-Uwe Möritz; Christoph Ritter; Katja A Arnold; Dieter Lutjöohann; Klaus von Bergmann; Ingrid Klöting; Michel Eichelbaum; Heyo K Kroemer
Journal:  Drug Metab Dispos       Date:  2005-08-17       Impact factor: 3.922

6.  Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice.

Authors:  Naomi Mizuno; Michiko Suzuki; Hiroyuki Kusuhara; Hiroshi Suzuki; Kenji Takeuchi; Takuro Niwa; Johan W Jonker; Yuichi Sugiyama
Journal:  Drug Metab Dispos       Date:  2004-09       Impact factor: 3.922

7.  Effect of protein binding on 4-methylumbelliferyl sulfate desulfation kinetics in perfused rat liver.

Authors:  M Chiba; K S Pang
Journal:  J Pharmacol Exp Ther       Date:  1993-08       Impact factor: 4.030

8.  Kinetic analysis of hepatobiliary transport for conjugated metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugated hyperbilirubinemia.

Authors:  O Takenaka; T Horie; K Kobayashi; H Suzuki; Y Sugiyama
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

9.  Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans.

Authors:  Masaru Hirano; Kazuya Maeda; Yoshihisa Shitara; Yuichi Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2004-05-24       Impact factor: 4.030

10.  Pravastatin transport across the hepatocyte canalicular membrane requires both ATP and a transmembrane pH gradient.

Authors:  Y Adachi; Y Okuyama; H Miya; H Matsusita; M Kitano; T Kamisako; T Yamamoto
Journal:  J Gastroenterol Hepatol       Date:  1996-06       Impact factor: 4.029

View more
  20 in total

1.  Fractional dynamics pharmacokinetics-pharmacodynamic models.

Authors:  Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-05-09       Impact factor: 2.745

Review 2.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

3.  Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).

Authors:  Anita Kort; Selvi Durmus; Rolf W Sparidans; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel
Journal:  Pharm Res       Date:  2015-01-08       Impact factor: 4.200

4.  Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics.

Authors:  Maribel Reyes; Leslie Z Benet
Journal:  J Pharm Sci       Date:  2011-05-26       Impact factor: 3.534

5.  Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys.

Authors:  Bridget L Morse; Jamus G MacGuire; Anthony M Marino; Yue Zhao; Maxine Fox; Yueping Zhang; Hong Shen; W Griffith Humphreys; Punit Marathe; Yurong Lai
Journal:  AAPS J       Date:  2017-10-10       Impact factor: 4.009

6.  Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.

Authors:  Thomayant Prueksaritanont; Xiaoyan Chu; Raymond Evers; Stephanie O Klopfer; Luzelena Caro; Prajakti A Kothare; Cynthia Dempsey; Scott Rasmussen; Robert Houle; Grace Chan; Xiaoxin Cai; Robert Valesky; Iain P Fraser; S Aubrey Stoch
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

Review 7.  Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Authors:  X Chu; K Korzekwa; R Elsby; K Fenner; A Galetin; Y Lai; P Matsson; A Moss; S Nagar; G R Rosania; J P F Bai; J W Polli; Y Sugiyama; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

Review 8.  ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Authors:  M J Zamek-Gliszczynski; C A Lee; A Poirier; J Bentz; X Chu; H Ellens; T Ishikawa; M Jamei; J C Kalvass; S Nagar; K S Pang; K Korzekwa; P W Swaan; M E Taub; P Zhao; A Galetin
Journal:  Clin Pharmacol Ther       Date:  2013-02-25       Impact factor: 6.875

9.  Mechanistic Modeling of the Hepatic Disposition of Estradiol-17β-Glucuronide in Sandwich-Cultured Human Hepatocytes.

Authors:  Katsuaki Ito; Noora Sjöstedt; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-11-19       Impact factor: 3.922

Review 10.  Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.

Authors:  Rui Li; Hugh A Barton; Manthena V Varma
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.